Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20063481 | 0.82 | SCN9A (0.43) | SCN9AHTR2CKDM1AMAOBHTR2A | |
| SCHEMBL20072886 | 0.77 | HTR2C (0.44) | SCN9AHTR2CKDM1AMAOBHTR2A | |
| SCHEMBL20073175 | 0.76 | SCN9A (0.42) | SCN9ATACR1KDM1AMAOBMAOA | |
| SCHEMBL20072884 | 0.76 | SCN9A (0.42) | SCN9ATACR1KDM1AMAOBMAOA | |
| SCHEMBL15777549 | 0.73 | KDM1A (0.60) | HTR2CKDM1AMAOBMAOA | |
| SCHEMBL20095495 | 0.72 | HTR2C (0.39) | SCN9AHTR2CHTR2AHTR2BHRH3 | |
| SCHEMBL20063390 | 0.71 | SCN9A (0.51) | SCN9AHTR2C | |
| SCHEMBL20072933 | 0.70 | SCN9A (0.34) | SCN9A | |
| SCHEMBL20095682 | 0.70 | HTR2C (0.49) | HTR2CHTR2AHTR2BHRH3 | |
| SCHEMBL20072866 | 0.70 | SCN9A (0.34) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | SCN9A 1478/4885TACR1 65/4885HTR2C 1243/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | SCN9A 1501/4885TACR1 66/4885HTR2C 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.